Werfen Life Group, SA
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Werfen Life Group, SA
Biogen's Return Of Rights To InnoCare Deals Blow To Made In China Innovation
Biogen’s return of rights to the BTK inhibitor orelabrutinib to originator InnoCare signals an ongoing tough reality for Chinese biotechs with go-global ambitions.
Ex-Sanofi Partnering Chief Wants AI Start-Up Owkin To Be Industry Leader
Having led $30bn of acquisitions of companies at Sanofi, the new challenge for its former global head of partnering is to help make Owkin, “the most disruptive AI biotech company in the world,” he tells Scrip.
Five Multiple Sclerosis R&D Updates From ECTRIMS
With the virtual doors about to close on the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting, Scrip takes a look at some of the highlights, including data for Merck KGaA and Sanofi’s new BTK inhibitors and research showing the impact of MS therapies on COVID-19 vaccine response.
Novartis Scores Another CSU Success With Remibrutinib
The Swiss group believes that remibrutinib, as well as its investigational IgE antibody ligelizumab, will complement standard of care Xolair and help it build a strong franchise for chronic spontaneous urticaria.
Diagnostic Imaging Equipment & Supplies
- Digital Imaging
- Diagnostic Imaging Equipment & Supplies
- Other Names / Subsidiaries
- Accriva Diagnostics
- ITC Nexus Holding Company
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.